Benitec Biopharma Price to Book Ratio 2014-2021 | BNTC

Historical price to book ratio values for Benitec Biopharma (BNTC) over the last 10 years. The current price to book ratio for Benitec Biopharma as of October 22, 2021 is 1.39.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Benitec Biopharma Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2021-10-22 3.54 0.01
2021-06-30 4.25 $488.05 0.01
2021-03-31 5.17 $455.42 0.01
2020-12-31 3.00 $644.27 0.00
2020-09-30 6.28 $1,396.39 0.00
2020-06-30 7.91 $2,047.60 0.00
2020-03-31 3.93 0.00
2019-09-30 7.11 0.00
2017-09-30 21.70 $21.68 1.00
2016-09-30 14.00 $30.63 0.46
2016-06-30 12.68 0.00
2016-03-31 17.10 0.00
2015-12-31 40.20 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.029B $0.000B
Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76